Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study).
To test the hypothesis that a dietary omega-3 fatty acid, docosahexaenoic acid, improves the lipoprotein subclass profile of children who have hyperlipidemia, we conducted a randomized, double-blind, placebo-controlled study. Children who had hyperlipidemia (n = 20) were stabilized on a low-fat diet for 6 weeks and then randomized to receive 1.2 g/day of docosahexaenoic acid for 6 weeks or placebo. Supplementation with docosahexaenoic acid significantly increased low-density lipoprotein subclass 1 and high-density lipoprotein subclass 2 (large and buoyant; less atherogenic particles) by 91% and 14%, respectively, compared with the placebo phase. Low-density lipoprotein subclass 3 (small and dense; more atherogenic particles) decreased by 48%.
Engler
Marguerite M
MM
University of California at San Francisco, San Francisco, California, USA.
Engler
Mary B
MB
Malloy
Mary J
MJ
Paul
Steven M
SM
Kulkarni
Krishnaji R
KR
Mietus-Snyder
Michele L
ML
D000293:Adolescent; D000328:Adult; D002648:Child; D018592:Cross-Over Studies; D019587:Dietary Supplements; D004281:Docosahexaenoic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006950:Hyperlipidemia, Familial Combined / Q000188:drug therapy*; D008074:Lipoproteins / Q000145:classification / Q000187:drug effects; D008297:Male
D008074:Lipoproteins; D004281:Docosahexaenoic Acids